4-(2-萘)哌啶盐酸盐 | 198334-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(2-萘)哌啶盐酸盐
• 英文名称: 4-(naphthalen-2-yl)piperidine hydrochloric salt
• 英文别名: 4-(2-naphthyl)piperidine HCl；4-(2-Naphthyl)piperidine hydrochloride；4-naphthalen-2-ylpiperidine;hydrochloride
• CAS: 198334-39-3
• 化学式: C₁₅H₁₇N*ClH
• 分子量: 247.768
• InChiKey: IRDSROWCEHZHKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(2-萘)哌啶盐酸盐 生成 (2R,4S)-2-methyl-4-(2-naphthyl)piperidine
  参考文献：
  名称：

  Process for preparing trans-2,4-disubstituted piperidines

  摘要：

  本发明提供了一种制备式（I）化合物的方法，其中R代表C1-C4烷基；X代表烷基，烯基，环烷基，芳基，取代芳基，杂环或取代杂环，包括用适当的冠醚和适当的碱处理式（II）化合物，随后加入式R-M+的化合物，其中M+是适当的阳离子。

  公开号：

  US20030092733A1

文献信息

• Synthesis of PEG-Functionalized Amines Using Ruthenium-Catalyzed Hydrogen Borrowing
  作者：Federico V. Rossi、Jeremy T. Starr、Daniel P. Uccello、Jennifer A. Young

  DOI：10.1021/acs.orglett.0c01965

  日期：2020.8.7

  increasingly important in medicinal chemistry. Herein, we describe the PEG functionalization of amines via hydrogen borrowing reductive amination. This was accomplished using the [Ru(p-cymene)Cl2]2 catalyst and phosphorus-containing ligand dppf or DPE to yield a variety of PEGylated primary and secondary amine products. Furthermore, we illustrate the utility of this method with the synthesis of quetiapine

  聚乙二醇（PEG）部分在药物化学中变得越来越重要。在这里，我们描述了通过氢借还原胺化的胺的PEG官能化。这是使用[Ru（p- Cymene）Cl 2 ] 2催化剂和含磷配体dppf或DPE完成的，以产生各种PEG化的伯胺和仲胺产物。此外，我们以62％的分离产率说明了喹硫平（Seroquel）的合成方法的实用性。
• [EN] ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] ARYLPIPÉRIDINES EN TANT QUE MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191384A1

  公开（公告）日：2021-09-30

  Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.

  化学式（I）的芳基哌啶化合物，以及其药用可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、障碍和情况的方法，例如与疼痛、精神障碍、神经系统障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征、躁郁症）、癌症和眼部疾病相关的情况：其中X、R2a、R2b、R3、R4、R5a和R5b的定义如本文所述。
• Agent for prevention and/or treatment of skin diseases
  申请人：Yamamoto Keisuke

  公开号：US08729264B2

  公开（公告）日：2014-05-20

  Provided is an agent for the prevention and/or treatment of a skin disease containing, as an active ingredient, a pyrazolopyrimidine derivative represented by the formula (I) (wherein each symbol is as defined in the specification), or a pharmacologically acceptable salt thereof, and the like.

  提供了一种用于预防和/或治疗皮肤疾病的药剂，其包含作为活性成分的吡唑嘧啶衍生物，其由式(I)所表示（其中每个符号如规范所定义），或其药理学上可接受的盐等。
• NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3321256A1

  公开（公告）日：2018-05-16

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗自身免疫性疾病（如类风湿性关节炎等）、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• Imide derivatives and use thereof as medicine
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10407408B2

  公开（公告）日：2019-09-10

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗类风湿性关节炎等自身免疫性疾病、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。